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Abstract: Pseudomonas aeruginosa is the most frequent cause of infection among non-fermenting 
Gram-negative bacteria, predominantly affecting immunocompromised patients, but its pathogenic 
role should not be disregarded in immunocompetent patients. These pathogens present a concern-
ing therapeutic challenge to clinicians, both in community and in hospital settings, due to their in-
creasing prevalence of resistance, and this may lead to prolonged therapy, sequelae, and excess 
mortality in the affected patient population. The resistance mechanisms of P. aeruginosa may be clas-
sified into intrinsic and acquired resistance mechanisms. These mechanisms lead to occurrence of 
resistant strains against important antibiotics—relevant in the treatment of P. aeruginosa infections—
such as β-lactams, quinolones, aminoglycosides, and colistin. The occurrence of a specific resisto-
type of P. aeruginosa, namely the emergence of carbapenem-resistant but cephalosporin-susceptible 
(Car-R/Ceph-S) strains, has received substantial attention from clinical microbiologists and infec-
tion control specialists; nevertheless, the available literature on this topic is still scarce. The aim of 
this present review paper is to provide a concise summary on the adaptability, virulence, and anti-
biotic resistance of P. aeruginosa to a readership of basic scientists and clinicians. 
Keywords: Pseudomonas aeruginosa; MDR; colistin; cephalosporin; carbapenem; virulence; biofilm; 
therapy 
 
1. Introduction, Taxonomy, and Microbiology of Pseudomonas aeruginosa 
1.1. General Concepts 
Non-fermenting Gram-negative bacteria (NFGNB) are a taxonomically heterogenous 
and populous group of Proteobacteria [1]. While the phenotypic characteristics of these 
microorganisms may be quite distinct, most of the NFGNBs are obligate aerobic, motile 
(presenting with polar or peritrichous flagella, with the exception of Burkholderia mallei, 
which is non-motile), and oxidase-positive (i.e., they use simple carbohydrates, e.g., glu-
cose in an oxidative fashion) rods. In addition, they are all similar in that they are unable 
to ferment sugars (hence the name of the group) to generate energy for their vital biolog-
ical functions [2,3]. NFGNB include some commonly isolated genera, such as Pseudomo-
nas, Acinetobacter, the Burkholderia cepacia complex (BCC), and Stenotrophomonas (Xan-
thomonas) maltophilia; nevertheless, other less frequently isolated genera should also be 
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taken into consideration, e.g., Achromobacter, Alcaligenes, Brevimundas, Elisabethkingia, Fla-
vobacterium, and Ralstonia [4–6].  
1.2. Taxonomy and Phenotypic Characteristics of P. aeruginosa 
Based on phenotypic characteristics, Gilardi has classified NFGNB into seven main 
groups, while Palleroni has differentiated five distinct homologous rRNA groups 
(namely, I.: Pseudomonas, II.: Burkholderia, III.: Comamonas, IV.: Brevimundas, and V.: Steno-
trophomonas) based on rRNA-DNA homology [7,8]. P. aeruginosa was first isolated from 
green pus by Gessard in 1882, while the genus Pseudomonas was first described by Migula 
in 1894, with P. aeruginosa being the species type of the genus [9]. Members of the Pseudo-
monaceae family are ubiquitous in nature (soil, plants, and aquatic environments, while 
birds and smaller mammals have also been described as reservoirs) [10–12]. P. aeruginosa 
is the most common cause of infections (both within the genus and among NFGNB) in 
humans and warm-blooded animals (e.g., urinary tract infections, mastitis, and endome-
tritis in livestock and companion animals) [13]. Other members of the genus are relevant 
as fish pathogens, causing hemorrhagic septicemia and ulcerative syndrome [14,15]. P. 
fluorescens and P. putida have been described as a cause for deterioration of refrigerated 
food, and as contaminants in blood transfusion and infusion preparations. P. stutzeri, P. 
mendocina, P. fulva, and P. monteilii are rarely pathogenic in humans (described in patients 
with end-stage disease and in septicemia), while P. baetica, P. syringae, P. plecoglossicida, 
and P. viridiflava are important plant pathogens [16–18].  
P. aeruginosa is a non-fastidious microorganism that does not require special cultiva-
tion conditions. It grows well on most non-selective (Mueller-Hinton, Nutrient agar, Lu-
ria-Bertani, blood agar, etc.) media, although there are some media which are used specif-
ically for the purpose of selective propagation of Pseudomonas (e.g., cetrimide agar, King-
A, and King-B media). While the microorganism grows best at 37 °C, pseudomonads can 
also survive in a wide temperature range (4–40 °C) [19,20]. Among the phenotypic char-
acteristics of P. aeruginosa, the characteristic odor (described as flower-like, “grape juice”, 
or “fresh tortilla”), β-haemolysis (on blood agar), and color of the colonies (in appropriate 
culture media) allows for their quick organoleptic identification [21]. P. aeruginosa and 
other members of the genus are known to produce various pigments, including pyover-
dine/fluoresceine (a fluorescent green-yellow water-soluble pigment, produced by 70–
80% of isolates, which also acts as a siderophore in low-iron conditions), pyocyanin (a 
green-blue lipid-soluble phenazone-derivative pigment, with roles in iron metabolism, in 
maintaining the redox-equilibrium surrounding the bacteria, and in cell–cell communica-
tion), pyorubin (a red-brown water-soluble pigment, produced by 2–3% of isolates, with 
roles in maintaining the redox-equilibrium), and pyomelanin/alkaptomelanin (a brown-
black, water-soluble, and acidic pigment) [22–25] (Figure 1). It has been shown that high 
phosphate concentration in the culture media induces pigment production in Pseudomonas 
spp. [26,27]. 
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Figure 1. P. aeruginosa antimicrobial susceptibility testing using disk diffusion on Mueller-Hinton 
agar plates. The isolate on the upper portion of the figure produces pyorubin and pyomelanin, while 
the isolate on the lower portion of the figure produces pyocyanin. 
2. Virulence Determinants of P. aeruginosa and Modulation of Virulence Factor Ex-
pression 
2.1. Genome of P. aeruginosa 
The pathogenicity of P. aeruginosa is supported by numerous virulence determinants, 
some of which are integral parts of their cell structure. On the other hand, many additional 
virulence factors are synthesized and excreted, depending on the environment surround-
ing the pathogen [28,29]. One of the most important characteristics of P. aeruginosa is its 
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adaptability to diverse natural environments and to harsh (in vivo) conditions, which con-
curs with high metabolic diversity among species of this genus [30]. The publication of 
the first sequenced genome of the opportunistic pathogenic strain P. aeruginosa PAO1 (iso-
lated from a wound) by Stover et al. in 2000 had paramount importance in shedding light 
on the physiology and virulence capabilities of this pathogen [31,32]. Since then, the com-
plete genome of many other species of the genus (P. putida KT2440, P. fluorescens Pf-5, P. 
fluorescens PfO-1, P. entomophila L48, and others) have been published [31,32]. In compar-
ison with a common Gram-negative isolate, namely the uropathogenic Escherichia coli 
(UPEC) (with a genome of ≥5 Mb) [33,34], P. aeruginosa has a large genome with 5.5–7 Mb, 
characterized by pronounced genomic plasticity [35,36]. This genetic repertoire includes 
a conserved core genome of ~4 Mb, while the remaining genetic material comprises of 
various sets of rare genes and gene islands [37]. The versatility of this pathogen is largely 
determined by the latter group of genes.  
The P. aeruginosa genome resembles a classical “secretor” genome, which includes a 
large proportion of regulatory genes (i.e., efflux pumps and other transport proteins, mo-
tility, chemotaxis), genes controlling metabolic pathways (which allows for adapting to 
distinct metabolic states), and genes encoding a plethora of virulence factors and antibiotic 
resistance determinants [38,39]. For example, cystic fibrosis—the defect of the cystic fibro-
sis (CF) transmembrane conductance regulator (CFTR) genes—leads to the accumulation 
of succinate in the lungs, which favors the colonization and survival of P. aeruginosa, as 
this microorganism can utilize it as a nutrient source [40]. Secreted virulence factors and 
proteases are some of the hallmarks in P. aeruginosa pathogenicity, which take up ~3% of 
the open reading frames of the P. aeruginosa PAO1 genome [31,32,41]. The diversity of the 
P. aeruginosa genome is further enhanced by the introduction of mobile genetic elements 
via horizontal gene transfer (HGT; such as conjugative transposons, insertion sequences, 
and genomic islands) [42]. P. aeruginosa also has an innate way to increase genetic diver-
sity in hypermutable strains: the DNA-mismatch repair system in these microorganisms 
consist of a protein trimer (namely the MutS-MutL-UvrD trimer), with the role of main-
taining genomic integrity in these species [43,44]. It has been suggested that species with 
mutations in this repair system result in “hypermutator” strains, where the spontaneous 
mutation rate is increased 1000×. These isolates are principally seen in the lung of CF pa-
tients and they are characterized by phenotypic changes (i.e., the so-called “mucoid” phe-
notype) and high-level antibiotic resistance [45,46]. 
2.2. Virulence Factors of P. aeruginosa 
Similar to other Gram-negative bacteria, lipopolysaccharide (LPS, or endotoxin), 
Type IV pili and flagella, adhesins, and lectins are all integral parts of the external cell wall 
structure of P. aeruginosa [47,48]. Based on the O-specific polysaccharide side chain of the 
LPS, 27 antigen groups may be differentiated, while there is also an opportunity to classify 
these bacteria based on their flagellar H-antigens [49]. The feature of motility for P. aeru-
ginosa is recognized as an advantage, as it is able to move from one niche to another with 
no difficulty [47–49]. Three types of motility, including swarming, swimming, and twitch-
ing motility, enable P. aeruginosa to be present in a wide range of different habitats with a 
diversity of environmental factors [50]. Lectins are proteins on the outer membrane of P. 
aeruginosa, which recognize glycosylated carbohydrates on host tissues, aiding the adher-
ence of bacterial cells. For example, LecA (which binds to galactose) and LecB (which 
binds to fucose) mediate the adherence of this pathogen to epithelial cells in the lung 
[51,52]. These cell-mediated virulence determinants have important roles in the initial 
phase of colonization, persistence, and in the establishment of infections in vivo [53]. Nev-
ertheless, the overwhelming majority of virulence determinants associated with P. aeru-
ginosa are secreted factors. These may be synthesized and secreted to the vicinity of these 
bacteria (damaging surrounding tissues and immune cells). In addition, they may be in-
troduced directly into host cells via a type III secretion system (T3SS) [54–56]. Secreted 
virulence factors are relevant in the later stages of the infection and invasion, during 
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which bacterial cells proliferate and subsequent damage occurs in tissue cells at the ana-
tomical site of infection, and the host immune response is dampened [57].  
These secreted virulence factors in P. aeruginosa include: (i) pigments (described pre-
viously), siderophores (e.g., achromobactin), and inorganic compounds (e.g., hydrogen 
cyanide), which have roles in iron scavenging, protection against damage caused by reac-
tive oxygen species (ROS; originating from immune cells), and competition against other 
bacterial genera. (ii) Exotoxins, including effector cytotoxins such as exotoxin A (ETA), 
exotoxin S (ExoS; inhibits the function of innate immune cells and neutrophil granulo-
cytes), exotoxin U (ExoU; phospholipase activity, which rapidly leads to cell lysis and has 
roles in inducing septic shock), and other exotoxins with similar functions (ExoT: inhibits 
cell division in mammalian cells and affects wound healing processes, ExoY: induces pro-
apoptotic processes, and exolysin A (ExlA), which is secreted by a two-partner secretion 
system (TPS)). (iii) Proteases and other enzymes: lipases, alkaline protease, elastase A 
(LasA), and B (LasB), heat-stable hemolysin/phospholipase H (PLH), phospholipase C 
(PLC), and DNase. (iv) Secretion systems: P. aeruginosa is known to have 5 types of secre-
tion systems, among which, Types I (T1SS), II (T2SS), and III are involved in the virulence 
of this pathogen. T1SS and T2SS are relevant in the secretion of various proteases and 
lipases, ETA, LasA, LasB, and PLH. On the other hand, there are two distinct T3SSs in P. 
aeruginosa: the role of fT3SS is to expel flagellar proteins (to aid in motility, and they may 
also play a role in biofilm formation), while the iT3SS is a needle-like protein (“injec-
tasome”), which introduces the previously mentioned effector toxins (such as ExoU and 
ExoS) into the cytoplasm of mammalian cells [42,54–63]. (v) Biofilm (see Section 2.4). In 
contrast to cell-mediated virulence factors (which are considered to be constitutive), the 
production of secreted virulence factors is largely dependent on the environmental factors 
and the niche surrounding the pathogen. 
2.3. Typing Methods for the Differentiation of P. aeruginosa Clones, Global Dissemination 
Many methods (with various costs, labor-intensity, and discriminatory power) have 
been proposed for the assessment of genetic similarity in P. aeruginosa, which are just as 
important for local infection control interventions and outbreak control as they are rele-
vant in the assessment of successful national or global clones by public health microbiol-
ogy [64,65]. These methods include serotyping, phage typing (based on the differential 
sensitivity to these isolates to standardized bacteriophages), pyocin typing, pulse-field gel 
electrophoresis (PFGE), field-inversion gel electrophoresis (FIGE), random amplified pol-
ymorphic DNA polymerase chain reaction (RAPD-PCR), oligonucleotide microarrays, 
multi-locus sequence typing (MLST), and whole-genome sequencing (WGS) [66–68]. 
While the latter three methods are relevant in the identification of internationally success-
ful P. aeruginosa clones, the other listed typing methods are used in the assessment of local 
outbreaks. Currently, three major international multidrug-resistant (MDR) clones have 
been identified, which have shown the most successful spread around the globe, namely 
the ST111, ST175, and ST235 clones [69,70]. ST111 (characterized by serotype O12) and 
ST235 (characterized by serotype O11) have been described on almost every continent of 
the world, while ST175 (characterized by serotype O4) has only been detected in European 
countries [69,70]. 
ST235 clones are known as highly virulent—owing to the presence of ExoU in these 
strains—and these isolates are MDR; thus, the therapy of these infections is also consider-
ably more difficult. Generally, it may be said that the continuous expression of resistance-
determinants hinders the virulence of the microorganism; however, the fitness burden 
associated with maintaining the MDR-phenotype was observed to be lower in case of the 
ST235 clones [71]. Based on WGS analysis, P. aeruginosa isolates of clinical and environ-
mental origin may be grouped into three distinct resistotypes, namely PAO1, PA14, and 
PA7. PAO1 and PA14 are characterized by possessing the T3SS secretion system and the 
corresponding effector toxins (ExoS but not ExoU in the case of PAO1, and ExoU but not 
ExoS in the case of PA14). On the other hand, PA7 does not have the T3SS; instead, they 
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utilize the TPS, by which they secrete the ExlA exolysin to damage surrounding tissue 
cells [72]. Some reports suggest that there may be an association between virulence and 
antibiotic resistance in P. aeruginosa isolates, as the carriage of the exoU genes was shown 
to correlate with resistance to aminoglycosides and fluoroquinolones. A possible explana-
tion was that the genomic island carrying exoU may also contain resistance-determinant 
genes [73,74]. 
2.4. Biofilm Formation 
Without a doubt, one of the most important virulence determinants in the pathogen-
esis of P. aeruginosa infections is the production of a biofilm. The biofilm allows for the 
adherence of these pathogens on various surfaces, provides protection from harsh envi-
ronmental conditions (e.g., sheer forces, drying), and from the immune system of the host 
(e.g., natural killer cells, phagocytes, complement, ROS-mediated damage) [75–77]. Bio-
films have heterogenous compositions, consisting of aggregates of sessile bacterial com-
munities (based on their composition, this may be monospecies or multispecies biofilm), 
exopolysaccharides (EPS; e.g., alginate, cellulose, dextran, rhamnolipids), environmental 
DNA (eDNA), carbohydrates, proteins, surfactants, lipids, various ions, and water [78,79]. 
The biofilm mode of growth was first described in the 1930s, while the true relevance of 
biofilm-embedded bacteria in infectious processes has been understood only in recent 
decades [80,81]. Bacterial cells usually attach to hydrophobic and/or coarse surfaces with 
the aid of their cell-mediated virulence determinants (e.g., pili, fimbriae, surface antigens), 
which is followed by the production of the protective EPS and other components [82]. 
Biofilms allow P. aeruginosa to persist in the external environment (in water pipes and 
tanks, sinks, on hospital tiles, on medical equipment, such as mechanical ventilators and 
respiratory tubing, humidifiers, dialysis equipment and catheters, endoscopes and im-
planted medical devices, in medical preparations, such as irrigation solutions, dialysis 
fluid, contact lens fluid, antiseptic solution, cremes) and in vivo [75–79,83,84].  
Biofilm formation is a critical attribute of P. aeruginosa in being a successful nosocom-
ial pathogen and it is also an important hallmark of chronic bacterial persistence. This may 
be observed in dental caries on the tooth surfaces [85,86], in skin and soft tissue infections 
[52], in infections of the middle ear [87], catheter-associated infections [19], pneumonia, 
and in the lungs of CF patients [88]. In the latter case, P. aeruginosa is able to survive and 
avoid clearance (withstanding the immune response and the subsequent administration 
of antimicrobials) in the respiratory and conductive zone of the lungs [89,90]. For example, 
alginate and other polysaccharides produced by the mucoid variants are effective in scav-
enging ROS, protecting bacterial cells [91]. Other than the protection against immune cells, 
the biofilm provides a safe haven for microorganisms against antibiotics in vivo, contrib-
uting to the MDR phenotype. It has been noted by several publications that the minimum 
inhibitory concentrations (MICs) of bacteria inside the biofilm may be 10–10,000 times 
higher, compared to planktonic cells [75–79,83,84,88–90]. On one hand, the secreted extra-
cellular matrix significantly hinders the diffusion of the antibiotic molecules to effectively 
reach the bacterial targets (pharmacokinetic barrier); in addition to this, bacteria residing 
in the deeper layers of the biofilm will adapt to a differentiated metabolic state [75–
79,83,84,88–90]. It must be noted that the inhibition of bacterial growth is mechanistically 
distinct from bacterial killing, and antimicrobials (even in effective doses) may not kill 
cells inside a biofilm. Due to the high bacterial density, low oxygen tension, and lack of 
nutrients, bacteria become dormant and utilize alternative metabolic pathways [91]. 
In addition to lacking cell motility, these “persister” cells (also termed small-colony 
variants (SCVs)) correspond to a transient phenotypic variant of bacteria, which are not 
genetically resistant to antibiotics, but under the abovementioned conditions, they can 
withstand very high concentrations of these drugs (pharmacodynamic barrier) [92–95]. In 
essence, persisters (corresponding to 1–2% of the bacterial population) opt not to prolifer-
ate during exposure to antibiotics, but they resume replication if the stressors are removed 
from the environment [92–95]. Persisters may also be important in the recurrence and 
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chronicity of P. aeruginosa infections. Although there is scarce knowledge on the mecha-
nisms leading to dormancy/persister formation, it has been suggested that the secretion 
systems may have a role [96]. The therapy of biofilm infections is an important challenge, 
as there is currently no targeted therapy available to completely eradicate biofilms in vivo. 
Nevertheless, several compounds (e.g., polyvalent anions, DNases like dornase-α and al-
ginate lyase) may be useful in the reduction of mucus density [97]. On the other hand 
(although the evidence on this topic is still controversial), some experiments have shown 
that sub-MIC concentrations of some antibiotics (mainly β-lactams, including ceftazidime, 
cefepime, imipenem, and meropenem) may have the opposite effect, inducing biofilm 
production [98–100]. P. aeruginosa also displays the ability to tolerate biocides (e.g., anti-
septics and disinfectants) like chlorhexidine or triclosan, mediated by the fabV gene, cod-
ing for a triclosan-resistant enoyl-acyl-carrier protein. Lack of susceptibility to biocides 
further hinders successful elimination of P. aeruginosa from hospital environments 
[101,102].  
2.5. Quorum Sensing (QS)-Mediated Control of Virulence Factor Expression in P. aeruginosa 
To allow for the continuous adaptation of P. aeruginosa to different environmental 
niches and to the different stages of infection, the secretion of the abovementioned viru-
lence factors needs to be tightly regulated. One of the most important regulators in P. 
aeruginosa is by its quorum sensing (QS) systems [103]. QS corresponds to the “social be-
havior” of bacteria, during which small signal molecules (termed autoinducers) are used 
to influence gene expression in bacterial cells, in a cell-to-cell and density-dependent man-
ner [104,105]. If the density of the bacterial population (hence, the concentration of these 
signal molecules) reaches a certain threshold, changes occur in bacterial physiology to aid 
collective behaviors or to help microorganisms to outcompete other microorganisms in 
the ecological niche (e.g., by secreting virulence factors or antibacterial compounds) 
[106,107]. Four interconnected systems, namely the iqs, las, pqs, and rhl pathways, compose 
the QS-regulatory network of Pseudomonas species. In this network, various autoinducers 
(such as acyl-homoserine lactones (acyl-HSLs), like butanoyl homoserine lactone (C4 
HSL) and 3-oxodecanoyl homoserine lactone (C12 HSL)), the B. cepacia complex fatty acid 
molecule named diffusible signal factor (BDSF), oligopeptide-type autoinducers (like au-
toinducer-2 (AI-2)), the Pseudomonas quinolone signal molecule (PQS), and integrated QS 
signal molecule (IQS)) are utilized. The detailed description of these signal molecules is 
outside of the scope of this review (for details, see References [103–113]). Additionally, 
these autoinducer molecules are capable of dampening the innate immune response and 
inducing cytokines and chemokines [114]. As the production of biofilm and the secretion 
of other virulence factors are all governed by the complex QS system of P. aeruginosa, they 
have significant influence on the virulence of these bacteria. QS mediates the expression 
of its pigments, alkaline protease, hemolysin, elastase, lectins, the effector exotoxins, exo-
toxin A, swimming and twitching motilities, the activity of the T1SS and T2SS (the activity 
of T3SS is influenced by QS to a lesser extent), production of biofilm, and hydrogen cya-
nide, among others [115,116]. QS is also an important mediator of the reciprocity between 
bacterial virulence, antibiotic resistance, and microbial fitness [117]. The complexity of P. 
aeruginosa pathogenicity is represented in Figure 2. 
Antibiotics 2021, 10, 42 8 of 28 
 
 
Figure 2. Main components of P. aeruginosa pathogenicity. 
Nonetheless, it is well-known that the upkeep of many resistance determinants and 
virulence factors may bear high fitness costs, leading to more susceptible strains outcom-
peting MDR ones [103–113,116,117]. Conversely, therapeutic and sub-inhibitory doses of 
antibiotics (e.g., ceftazidime, cefepime, imipenem, fluoroquinolones, doxycycline) may 
eradicate various QS signal molecules or inhibit their binding to the relevant receptors; 
thus, suppressing their virulence [118,119]. In addition to QS, biofilm production is also 
mediated by various two-component regulatory systems (GacS/GacA, RetS/LadS) and cy-
clic diguanylate (cyclic-di-GMP; a cyclic dimeric guanosine monophosphate), with the 
signal molecule having critical roles in the secretion of EPS [120]. If these bacteria adhere 
to any in vivo or inanimate surfaces, the concentration of cyclic-di-GMP increases, leading 
to the expression of “static” determinants, such as adhesive pili (securing attachment to 
the surface) and the subsequent production of biofilm. At the same time, increased cyclic-
di-GMP also results in the repression of the synthesis and function of flagella (“motility” 
determinants) [120,121]. This leads to the thickening of the initial biofilm, corresponding 
to protection against immune cells and antimicrobials.  
2.6. Clinical Relevance of P. aeruginosa 
As described previously, P. aeruginosa has the means to migrate, evade host immune 
responses and noxius antimicrobial agents, produce toxins and exoenzymes to damage 
the host cells, and to successfully adapt to any environment [122]. In the consideration of 
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global epidemiological features of NFGNB, P. aeruginosa is the most frequent cause of in-
fections [123,124]. Even though pseudomonads do possess various virulence factors, 
when compared to members of the Enterobacterales order or to other bacteria more com-
monly seen as pathogens (e.g., Staphylococcus aureus, Streptococcus pyogenes), they are not 
considered as highly pathogenic. Nevertheless, they may still be responsible for a wide 
range of disease manifestations and these pathologies often manifest as chronic, hard-to-
eradicate infections [125,126]. Multisite infections are also common for P. aeruginosa. Per-
sons affected are most commonly immunocompromised patients (affected by other dis-
eases or underlying conditions, see Table 1), but its pathogenic role should not be disre-
garded in immunocompetent patients [125–130]. P. aeruginosa is mainly considered an op-
portunistic, nosocomial Gram-negative pathogen (responsible for 13–19% of hospital-ac-
quired infections in the US), which is commonly found in intensive care units (ICUs) and 
surgical theaters, where the extensive use of antimicrobials has allowed for the selection 
of these microorganisms [131]. Practically all healthcare institutions have reported P. ae-
ruginosa outbreaks and intrahospital infections, as these bacteria have the ability to persist 
on a plethora of inanimate surfaces and to spread via an aerosol [132]. Under normal cir-
cumstances, P. aeruginosa can only transiently colonize the intestinal tract (although this 
rate may increase if the patient is immunocompromised). Nevertheless, 8–20% of noso-
comial infections and outbreaks are associated with colonized individuals [125]. To avoid 
nosocomial outbreaks, the strict adherence to infection control protocols, environmental 
cleaning plans, and hand hygiene practices are of critical importance, in addition to the 
identification and elimination of possible reservoirs of infection [125]. 
Table 1. Main risk factors for acquiring P. aeruginosa infections [125–130]. 
Hospitalization 
Mechanical ventilation 
Innate or acquired immunodeficiencies (neutropenia, human immunodeficiency virus 
[HIV]/acquired immunodeficiency syndrome [AIDS], malignancy)  
Invasive medical procedures (surgery, transplantation) 
Catheterization (urinary, central venous) 




Diseases of the cardiovascular system 
Diseases of the respiratory system (e.g., chronic obstructive pulmonary disease, cystic 
fibrosis) 
Diabetes mellitus 
Patients living in poor living conditions, malnutrition 
Intravenous drug use 
Possible clinical manifestations include pneumonia (mainly ventilator-associated 
(VAP; 10–30%), while the community-acquired form is far less common (CAP; 1–3%)), 
skin and soft tissue infections associated with burns and surgeries (8–10%), “hot tub” fol-
liculitis, “swimmer’s ear” otitis externa, eye infections (keratitis), urinary tract infections 
(UTI; 813.8615%), endocarditis, and bacteremia/sepsis (central-line-associated or often 
secondary to pneumonia) [125–130,133]. Among bacterial pathogens responsible for con-
tact lens-associated keratitis, P. aeruginosa has the worst disease manifestation (i.e., the 
development of a corneal ulcer, which may occur in 40–60% of cases), leading to poor 
outcomes, the fulminant destruction of the cornea, and vision loss [73,134,135]. The mor-
tality rate of pseudomonad infections is a big concern among immunocompromised and 
hospitalized patients, which is around 25–39% for pneumonia and 18–61% for bacteremia, 
while these rates may be higher (40–70%) in case of MDR isolates [136–138]. In some age 
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groups, these infections may have particularly severe manifestations (e.g., nosocomial 
pneumonia in the elderly, and severe sepsis and meningitis in neonates) [125–137]. The 
poor outcomes associated with these infections are corresponding to the severe condition 
of these patients and to the virulence factors of this pathogen. P. aeruginosa is also an im-
portant factor in the progression of chronic respiratory disorders, e.g., a systematic review 
has found increased hospitalization rate, higher exacerbation rate, worse quality of life, 
and 3-fold increase in the mortality risk in patients with bronchiectasis positive for P. ae-
ruginosa in their lungs [139]. P. aeruginosa was also found to be induced by cigarette smoke, 
which has led to the emergence of an nfxC drug-resistant phenotype [140].  
P. aeruginosa is the most common and oldest studied pathogen in CF. The first expo-
sure to pseudomonads may be related to a previous viral infection (which eliminates host 
defenses in the lungs even further) and the bacteria usually originate from some natural 
source (e.g., aerosols, water, bacterial flora of other individuals) [141]. P. aeruginosa strains 
that settle in the lungs of CF patients are initially not of the mucoid type; however, strains 
with a highly slimy surface and a mucoid phenotype are isolated 3–6 months later [142]. 
In CF patients, P. aeruginosa may only be eradicated in the early stages of colonization 
(which provides a ‘window of opportunity’ for early aggressive antibiotic treatment), 
while during chronic colonization or exacerbations at the later stages of life, the goal is to 
reduce the number of bacteria [141,142]. Age at first positivity for P. aeruginosa was shown 
to be an important determinant of the disease course in CF-affected individuals. The prev-
alence of the pathogen between 0 and 5 years of age is 10–30%, while over 25 years of age 
it is present in >80% of patients and these chronic lung infections are rarely eradicated 
completely. P. aeruginosa is one of the most important factors in fatal pulmonary exacer-
bations in CF patients [142]. P. aeruginosa is also an important pathogen in animal hus-
bandry, making it a considerable cause of economic losses and difficulty keeping up ani-
mal stocks for marketing purposes (see Section 1.2) [13–18,143]. 
3. Antibiotic Resistance in P. aeruginosa: Therapeutic Alternatives 
3.1. General Concepts Related to MDR Pathogens 
As a general rule, the therapy of infections caused by NFGNB present a concerning 
therapeutic challenge to clinicians both in community and in hospital settings, due to in-
creasing prevalence of resistant isolates, showing resistance to several classes of antibiot-
ics [144]. Nowadays, the emergence of isolates classified as MDR, extensive drug-resistant 
(XDR), and even pandrug-resistant (PDR, or totally drug-resistant (TDR), defined by the 
recommendations of the European Society of Clinical Microbiology and Infectious Dis-
eases; ESCMID [145]), is becoming commonplace in clinical practice. The burden of MDR 
bacteria—and the associated risks for humanity—have been highlighted by many na-
tional and international bodies (e.g., the World Health Organization (WHO) [146], the Eu-
ropean Center for Disease Control and Prevention (ECDC) [147], the UK National Health 
Service (NHS) [148], and the US Centers for Disease Control (CDC) [149]), stressing that 
without the availability of adequate therapy, these infections lead to prolonged hospitali-
zation, decreased quality of life (QoL), sequelae, and excess mortality in the affected pa-
tient populations. In many cases, poor clinical outcome is clearly associated with infec-
tions caused by MDR pathogens, compared to their susceptible counterparts [150]. The 
two main driving forces behind the clinical problem of antibiotic resistance is their indis-
criminate use in inappropriate indications, in addition to the dwindling interest of phar-
maceutical companies to get involved in antimicrobial research [151]. 
Although the problem of MDR was first observed in hospital-acquired infections, 
nowadays, it is not uncommon to acquire an infection with a MDR pathogen in the com-
munity [152]. The Burden of Antimicrobial Resistance Collaborative Group estimated that 
in the year 2015 alone, there were over 700,000 MDR infections, 33,110 excess deaths, and 
around 875,000 disability-adjusted life years (DALY) described in the European Union 
and European Economic Area [153]. MDR organisms also threaten the progress of the 
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Sustainable Development Goals (SDGs) set by the United Nations for 2030, having the 
most serious effects in developing countries [154]. P. aeruginosa—along with other 
NFGNB—is a member of the so-called “ESKAPE” pathogens (E: Enterococcus faecium, S: S. 
aureus or recently S. maltophilia, K: Klebsiella pneumoniae or recently C: Clostridioides difficile, 
A: A. baumannii, P: P. aeruginosa, E: Enterobacter spp., or recently Enterobacteriaceae): the 
acronym includes bacteria that are most concerning from a clinical and public health per-
spective [155]. This has been underlined by the report published by the WHO, in which 
carbapenem-resistant P. aeruginosa, carbapenem-resistant A. baumannii complex, and car-
bapenem-resistant or ESBL-producing members of Enterobacterales were all designated 
as critical priority pathogens [156]. The most worrisome reports in the international liter-
ature have emerged regarding MDR Acinetobacter spp.; nevertheless, due to its much 
higher incidence, the relevance of P. aeruginosa is more pronounced [157]. Recently, a PDR 
strain of Pseudomonas sp. strain has been described, which was capable of using ampicillin 
as a sole carbon source [158].  
3.2. Intrinsic Resistance and Main Therapeutic Alternatives in P. aeruginosa Infections 
The therapy of Pseudomonas infections heavily relies on a limited number of antibiot-
ics, and some recently marketed novel agents are relevant in case of extensive resistance 
(Table 2) [159,160]. The modes of antibiotic resistance in P. aeruginosa may be classified 
into three categories, including (i) adaptive (i.e., biofilm formation, dormant forms), (ii) 
intrinsic (see Table 2), and (iii) acquired resistance mechanisms (mutation or acquisition 
of integrons, plasmids, prophages, and transposons by the means of HGT), resulting in a 
rich and diverse resistome [161]. The occurrence of mutations may lead to antibiotic up-
take reduction, antibiotic target modifications, and over-expression of both efflux pumps 
system and antibiotic inactivating enzymes [162–164]. In essence—apart from the fluoro-
quinolones (who present with excellent oral bioavailability)—all of the present therapeu-
tic alternatives for P. aeruginosa need to be administered parenterally [165]. Clinically, in-
fections caused by Pseudomonas spp. are most frequently treated with β-lactam antibiotics: 
these drugs should be considered as the backbone of anti-infective therapy, especially in 
case of special patient groups (i.e., infants, young children, pregnant women, and in the 
elderly). In these patients, the use of other ancillary drugs is contraindicated, due to their 
adverse events (neurotoxicity and nephrotoxicity for aminoglycosides and colistin, and 
tendonitis, tendon rupture, photosensitivity, and hepatotoxicity for fluoroquinolones) or 
due to their teratogenicity [166,167]. If resistance levels become more and more advanced 
(or in the case of hypersensitivity to β-lactams), last-resort antibiotic regimens may be 
needed, which correspond to more severe adverse events and decreased quality of life 
(QoL) in the affected patients [168]. Nephrotoxicity is a critical concern in transplant pa-
tients, who receive several other medications affecting the kidneys [136]. In fact, a novel 
classification method for bacterial resistance termed difficult-to-treat resistance (DTR) 
takes into consideration the clinical usefulness and the risk/benefit ratio of antibiotics in 
the treatment of Gram-negative infections. Based on this criterion, Pseudomonas isolates 
resistant to broad-spectrum cephalosporins, carbapenems, and quinolones are termed 
DTR [169,170]. The risk factors for the acquisition of MDR P. aeruginosa include the admis-
sion to an intensive care unit (ICU), prior hospital stay, and previous use of various anti-
biotic groups (quinolones, cephalosporins, carbapenems) [171,172]. Interestingly, prote-
ases and elastases (two important virulence factors for the development of serious, inva-
sive disease) are also the most common in isolates originating from the ICU [173]. 
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Table 2. Intrinsic resistance and relevant therapeutic alternatives in Pseudomonas infections [159–165]. 
Antibiotics to Which Pseudomonas 
Species Are Intrinsically Resistant Antibiotics Relevant in the Therapy of Pseudomonas Infections 
Glycopeptides (e.g., vancomycin) 
β-lactam antibiotics: third and fourth generation parenterally administered 
cephalosporins (ceftazidime, cefepime, piperacillin/tazobactam), monobactams 
(aztreonam), carbapenems (imipenem, meropenem and doripenem), novel β-lactam/β-
lactamase inhibitor combinations (ceftolozane/tazobactam, ceftazidime/avibactam, 
imipenem/cilastatin/relebactam, meropenem/vaborbactam) 
Daptomycin 
Oxazolidinones (e.g., linezolid) 
Macrolides (e.g., azithromycin) 





Fluoroquinolones: ciprofloxacin, levofloxacin, moxifloxacin, delafloxacin 
Tetracycline 
Aminopenicillins 
Aminoglycosides, neoglycosides: gentamicin, tobramycin, amikacin, plazmomicin  Aminopenicillin/β-lactamase-
inhibitor combinations 
I–II. generation cepalosporins 
Polymyxins: colistin Orally administered III generation 
cephalosporins 
Currently, antibiotic dosing strategies (as they are primarily dosed aiming to cure) 
facilitate the emergence of resistant mutant subpopulations in bacteria; therefore, a change 
in clinical approach needs to occur to shift the endpoint of therapy towards killing and 
the suppression of resistance (which is mechanistically different from inhibition of 
growth) [174,175]. To achieve this, rapidly lethal agents to these microorganisms need to 
be applied in sufficently large doses, which also simultaenously results in a clinical cure 
[174,175]. 
3.3. Main Mechanisms of Resistance in P. aeruginosa to Antibiotics Other Than β-Lactams 
The Gram-negative cell wall is a complex construct of bacterial anatomy (including 
the asymmetric bilayer of phospholipid, penicillin-binding proteins (PBPs), porins (or 
outer membrane proteins (OMPs)), and other types of protein channels, LPS, and various 
efflux pumps), which acts as a selective barrier to be penetrated or bypassed for antibiotic 
molecules to be able to exert their pharmacological activities on their molecular targets 
[176]. The permeability of the P. aeruginosa outer membrane is restricted (10–150× lower 
than that of E. coli), leading to the intrinsic non-susceptibility to many previously listed 
agents (coupled with their efflux). In addition, any changes to the constituents of this cell 
wall structure will unavoidably affect the susceptibilities of antibiotics [177,178]. P. 
aeruginosa porins (β-barrel proteins folding within the outer membrane composed of anti-
parallel β-sheets) are classified into non-specific (OprF), specific (OprB, OprD or the D2 
porin, OprE, OprO, OprP), gated (OprC, OprH), and efflux (OprM, OprN, OprJ) porins 
[179]. Among different porins of P. aeruginosa, OprF is the most common non-lipoprotein 
within the outer membrane (the E. coli homolog porin is OmpA), which is involved in 
securing the integrity of the outer membrane, QS, biofilm formation, bacterial adhesion, 
and acute and chronic infections [179,180]. β-lactam antibiotics and fluoroquinolones 
enter bacterial cells through the abovementioned porin channels, aminoglycosides are 
taken up by a two-step process, involving the presence of oxygen- or nitrogen-dependent 
electron transport chains, while colistin facilitates its own uptake by interacting with the 
Gram-negative LPS [176–180]. The absence of oxygen (e.g., in the depths of a biofilm or in 
anaerobic bacteria) or the functional deficiency of ATPases may lead to resistance against 
aminoglycosides [181]. The most important porin in the context of antibiotic uptake is the 
OprD porin, which is a 54 kDa protein. Loss of the OprD porin (usually mediated by the 
inactivation of the OprD gene through deletions, mutations, or insertions) has been 
reported as one of the principal mechanisms of carbapenem resistance in Pseudomonas 
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[182]; in addition, imipenem selects for porin-deficient mutants in 1 out of 5 patients 
treated with this drug [183]. On the other hand, the overproduction of the OprH porin 
(which is the smallest porin of P. aeruginosa), coupled with cation-starvation, has been 
described in isolates with increased MICs to polymyxins and aminoglycosides [184].  
The over-expression of efflux pumps is a well-known contributor to the MDR 
phenotype, as it may affect many different groups of antibiotics at once [185]. Based on 
their protein structures, these efflux systems may be classified into five superfamilies, 
including the ATP-binding cassette (ABC) superfamily, multidrug and toxic compound 
extrusion (MATE) family, major facilitator superfamily (MFS), resistance-nodulation-
division (RND) family, and small multidrug resistance (SMR) family. On the other hand, 
they may also be divided into pumps dependent of hydrolyzing ATP to extrude relevant 
compounds or by utilizing the proton motive force (PMF) [186,187]. From the standpoint 
of antibiotic resistance in pseudomonads, members of the RND superfamily have the most 
importance: so far, twelve RND pumps have been described, out of which, the four over-
expression ones (mediated by mutations in the nalB, nfxB, and nfxC genes) are significant 
contributors with varying substrate profiles (MexAB-OprM: β-lactams and quinolones, 
MexCD-OprJ: β-lactams, MexEF-OprN: quinolones, and MexXY-OprM: aminoglycosides) 
[186]. Efflux pump-mediated resistance usually confers low-level resistance to relevant 
antibiotics, which will in turn lead to clinically relevant resistance, if combined with some 
other resistance mechanism [176,185–188]. It must be noted that the abovementioned 
resistance mechanisms may differently affect the in vitro susceptibility of P. aeruginosa to 
individual antibiotics (even in the pharmacological group): in clinical microbiological 
laboratories, it is often observed that some isolates are resistant to meropenem, but not 
imipenem, or resistant to amikacin, but not tobramycin [189]. Other than efflux pump 
overexpression, mutations in the target genes coding for DNA gyrase (gyrA, gyrB) and 
topoisomerase IV (parC, parE) in the QRDR (quinolone resistance-determining region) is 
the most important mechanism of resistance against fluoroquinolones, leading to 
decreased binding affinity of these proteins to the drugs [190].  
In addition to the previously described resistance mechanisms (efflux, decreased 
membrane permeability), the resistance against aminoglycosides may be mediated by 
target modification in the 30S ribosome, or by the production of aminoglycoside-
modifying enzymes (AMEs; e.g., nucleotidyltransferases, acetyltransferases, 
phosphotransferases), and 16S rRNA methyltransferases. These enzymes act via 
irreversibly modifying the chemical structure of these drugs (most commonly the amino 
and glycoside groups) [191,192]. These modifying enzymes are commonly acquired 
through HGT. Colistin is currently considered a last-resort, life-saving antibiotic for XDR 
Gram-negative infections, and due to the developments of antimicrobial resistance, the 
use of this agent is on the rise (despite the disadvantageous side-effect profile and difficult 
dosing of the drug) [193]. Before the early 2010s, colistin resistance was only described via 
mutations in chromosomal genes (i.e., ccrB, mgrB, pmrAB, phoPQ), which were transferred 
vertically [194]. Consequently, plasmid-mediated colistin resistance was detected in 2015, 
where a plasmid-borne transmissible mobile colistin resistance (mcr-1) plasmid was 
found [195]. This proved to be a critical concern, as the widespread dissemination of 
colistin resistance through mobile genetic elements was now a possibility. To date, ten 
different mcr genes (mcr-1 to mcr-10) have been described with many variants, from all 
countries apart from Antarctica [196]. This resistance is mediated by the arnBCADTEF 
operon, and results in the addition of 4-amino-4-deoxy-L-arabinose and 
phosphoethanolamine to the lipid A component of the Gram-negative LPS; this, in turn, 
will lead to the capacity of colistin to interact with the LPS, blocking the self-facilitation of 
uptake [197]. In case of low concentration of bivalent cations (Mg2+ and Ca2+), a two-
component regulatory system (PhoPQ and PmrAB) is activated, which also leads to 
colistin resistance [198]. 
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3.4. Main Mechanisms of β-Lactam-Resistance in P. aeruginosa 
As previously mentioned, β-lactams are the most commonly used therapeutic choices 
for Pseudomonas infections, with carbapenems often being the last safe therapeutic 
alternatives in many MDR infections [199]. This is especially true since the global 
emergence and spread of extended-spectrum β-lactamase-producing (ESBL) gut bacteria 
[200]. Due to the extensive use of these life-saving drugs, the emergence of carbapenem 
resistance in NFGNB and in gut bacteria (e.g., E. coli, Klebsiella, and Enterobacter species) is 
steadily increasing [201]. Among NFGNB, S. maltophilia has intrinsic carbapenem 
resistance (due to two chromosomally encoded metallo-β-lactamases), while in case of 
Acinetobacter and Pseudomonas, acquired mechanisms are more common [202,203]. Based 
on the results of a recent meta-analysis, the acquisition of carbapenem-resistant P. 
aeruginosa was associated with not only the prior use of carbapenems, but the history of 
receiving piperacillin-tazobactam and vancomycin [173]. β-lactam-resistance may be 
mediated by a plethora of resistance mechanisms, including mutations (downregulation 
or absence) in porin channels, efflux pump overexpression, and changes in the PBPs, with 
the most common being the expression of various β-lactamases (while many References 
stress that carbapenem resistance is usually caused by a combination of different factors) 
[204,205]. Nevertheless, β-lactamases show a very diverse spectra of activity and their 
potency is also influenced by their phenotypic expression levels in the isolates [206].  
Specific modifications in the PPBs may lead to decreased susceptibility to β-lactams, 
although this mechanism is less common compared to Gram-positive bacteria: alterations 
in PBP1 usually affect cephalosporins, PBP2 is important for both cephalosporins and 
carbapenems, changes in PBP3 affect the binding affinity of imipenem, while PBP4 is 
relevant to the binding of imipenem and meropenem [207]. Pseudomonas species are 
characterized by a chromosomally encoded ampicillin C-type (AmpC) β-lactamase, which 
is expressed at low levels under normal circumstances; however, the administration of 
many antibiotics may lead to this enzyme being induced and stably de-repressed (strong 
inducers include ceftazidime, carbapenem, and clavulanic acid (e.g., in ticarcillin-
clavulanate)), leading to high-level resistance to cephalosporins with anti-pseudomonal 
activity, while sparing carbapenems [208,209]. In addition, loss-of-function mutations in 
the ampD gene (which encodes for the repressor compound of AmpC-expression) also 
result in hyperproduction of this β-lactamase [210]. For this reason, Pseudomonas species 
are members of the “SPACE” organisms (Serratia, Pseudomonas, Acinetobacter, Citrobacter 
and Enterobacter), characterized by the presence of inducible AmpC-based resistance. 
AmpC activity is not inhibited by first-generation β-lactamase-inhibitors, such as 
clavulanic acid, sulbactam, or tazobactam [211]. Other than AmpC, Pseudomonas spp. may 
carry a plethora of narrow-spectrum or broad-spectrum β-lactamases. Among β-
lactamases, plasmid-borne carbapenemases (either serine- or metallo-β-lactamases) 
possess the broadest spectrum of substrates (including most penicillins, cephalosporins, 
and carbapenems); thus, they eliminate these drugs as possible therapeutic options 
[212,213]. While Ambler Class A carbapenemases, such as KPC (K. pneumoniae 
carbapenemase) and GES (Guiana Extended spectrum, especially GES-2), and Class D 
enzymes like members of the OXA-48-like family (Oxacillinase) may also be detected in 
carbapenem-resistant Pseudomonas, the principal type of carbapenemases is this genus are 
metallo-β-lactamases (MBLs) [214–216]. In fact, the first transferable carbapenem 
resistance determinant via MBLs was reported in a P. aeruginosa isolate in Japan (1991; 
Imipenemase 1, IMP-1) [217]. The discovery of IMP-1 was followed by the description of 
VIM-1 (1997; Verona Imipenemase 1, VIM-1) in a P. aeruginosa isolate [218]; in both cases, 
genes coding for the MBL were found on a gene cassette inserted into a class 1 integron. 
Since then, a variety of novel MBLs have been described in Gram-negative bacteria, 
including AIM (Australian Imipenemase), DIM (Dutch Imipenemase), GIM (German 
Imipenemase), KHM (Kyorin University Hospital), NDM (New Delhi MBL), SIM (Seul 
Imipenemase), SPM (Sao Paulo MBL), and TMB (Tripoli MBL) [219,220]. In laboratory 
conditions, carbapenemases may be differentiated through the inhibition of various 
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molecules (e.g., ethylenediaminetetraacetic acid for MBLs, boronic acid for serine-type 
enzymes), but it is more difficult to carry out due to the low outer membrane permeability 
of P. aeruginosa, which may significantly alter the resistance phenotype [221,222]. 
Carbapenem-resistant Pseudomonas is a major concern in low- and middle-income 
countries. Infections and colonization with carbapenem-resistant Gram-negative bacteria 
have been associated with increased economic costs, longer hospital stays, and poorer 
clinical outcomes compared to their carbapenem-susceptible counterparts [223]. Patients 
with bacteremia caused by carbapenem-resistant Pseudomonas had 3-times higher odds of 
mortality compared to the infections by carbapenem-susceptible species [224]. Based on 
the international literature, carbapenem resistance rates in Pseudomonas range between 
10% and 50%, with pronounced geographical differences [225]. The CDC has reported that 
carbapenem resistance rates were up to 12% in some parts of the US [226]. The population 
weighted mean proportion of carbapenem-resistant P. aeruginosa was 17.2% in 2018, while 
this ratio was 30.7% in China in the same year [144]. In Europe, Greece has a very high 
prevalence of carbapenem resistance in Pseudomonas (40.4% in 2015, based on the data of 
the European Antimicrobial Resistance Surveillance Network), which corresponds to the 
extensive use of these drugs [227]. Earlier reports (before 2000) highlighted the critical role 
of OprD inactivation and efflux pumps in carbapenem resistance, while newer reports 
show that carbapenemases are increasingly displaying a critical role [228]. The highly 
successful clone ST235 is one of the major carbapenem-resistant clones, which have spread 
worldwide. This clone usually carries metallo-β-lactamases, including IMP, NDM, and 
VIM enzymes [38,70,71]. 
3.5. Carbapenem-Resistant but Cephalosporin-Susceptible P. aeruginosa (Car-R Ceph-S) 
Resistotyping is a relatively old method of differentiation among bacterial strains, 
which has garnered new-found interest in the era of extensive resistance in bacteria [229]. 
The principle of resistotyping includes testing bacterial strains against arbitrarily selected 
chemical agents (i.e., clinically used antibiotics in microbiology laboratories) to 
differentiate them by the presence/absence of resistance to selected chemical substrates, 
whereby a resistance pattern—characteristic for the geographical region for those 
strains—is generated [229]. The occurrence of a specific resistotype of P. aeruginosa, 
namely the emergence of cephalosporin-susceptible (Car-R/Ceph-S) strains among 
carbapenem-resistant isolates, has received substantial attention from clinical 
microbiologists and infection control specialists; however, the available literature on this 
topic is still scarce. In the following section, our aim was to collect and summarize the 
currently available data at this time regarding this uncommon resistotype, including 
epidemiological papers and studies on their phenotypic and genotypic characterization. 
Most of the reports originate from the Far East, while some publications are also available 
from the European Continent and the Middle East.  
In a study spanning a three-year-long period, Ferreiro et al. recorded sixty-two (n = 
62) Car-R/Ceph-S cases causing nosocomial UTIs: the crude mortality rate in their study 
was also recorded, corresponding to 17.7% [179]. Shigemura et al. reported seventy-six (n 
= 76) patients (77.6% male patients) with a Car-R/Ceph-S P. aeruginosa UTI over four years 
[230]. Zeng et al. collected Car-R/Ceph-S P. aeruginosa in the second half of 2011, and they 
found n = 29 individual isolates. During their study, the isolates were characterized by 
Western blotting and real-time PCR (RT-PCR) methods. It was shown that the expression 
of AmpC-type β-lactamases and carbapenemases was not verified in these isolates, while 
the overwhelming majority showed decreased expression or deletion of the OprD porins 
as the major determinant of resistance [231]. Li et al. characterized Car-R/Ceph-S P. 
aeruginosa isolated from bacteremia over an 8-year (2010–2017) period: sixty-three isolates 
were collected, with most isolates presenting with overexpression of efflux pumps and 
decreased expression of OprD [232]. The findings of Li et al. corresponded to those of 
Zeng et al., as the production of relevant β-lactamases was not shown in these isolates 
either. The overall 30-day mortality rate between the years 2010 and 2017 was shown to 
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be 27.0% in the affected patients [231]. During the laboratory study by Wi et al., eighteen 
(23.3%) ceftazidime-susceptible isolates were found among imipenem-resistant P. 
aeruginosa strains. Overexpression of efflux pump genes (mexB, mexD, mexF, and mexY) 
was seen in 13/18 strains, 2/18 showed AmpC β-lactamase overexpression, while 
decreased oprD gene expression was identified in 18/18 strains [233].  
Two-hundred and ninety-three Car-R/Ceph-S P. aeruginosa isolates were 
characterized by Khuntayaporn et al. during a three-year study period. The observed 
prevalence of resistance determinants was the following: AmpC-type β-lactamase 
production 3.9%, metallo-β-lactamase (MBL) production 18.5%, efflux pump-
overexpression 63.5%, and decreased oprD gene expression 93.3%, respectively [234]. 
Campana et al. reported twenty-five individual Car-R/Ceph-S isolates from various types 
of clinical samples: >90% had reduced levels of oprD gene expression, while 
overexpression of efflux pumps or production of major types of β-lactamases (detected by 
the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry [MALDI-
TOF MS] method and RT-PCR) were not shown in these isolates [235]. Zaidenstein et al. 
reported sixty-seven Car-R/Ceph-S bloodstream infections from monobacterial clinical 
syndromes over a 5-year period (2010–2014). The authors have noted that in these cases, 
cephalosporins were considered as relevant therapeutic options [236]. Tsai et al. 
characterized n = 14 P. aeruginosa isolates, that were resistant to carbapenems only. 
Reduced OprD expression was found in 93% (14/15) of the isolates, being the major 
contributor to selective carbapenem resistance in these bacteria [237]. Pena et al. reported 
a nosocomial outbreak, caused by a cefepime and carbapenem-resistant, but ceftazidime-
susceptible, P. aeruginosa, affecting 23 patients in Spain. After molecular characterization 
of the isolate, it was found that it overexpressed the MexXY-OprM efflux pump and 
produced an integron-borne PSE-1 β-lactamase [238]. Pournaras et al. collected twelve 
Car-R/Ceph-S during the year 2003, and none of the strains were positive for 
carbapenemases; in contrast, 12/12 isolates were positive for mexB, 11/12 for mexY, while 
10/12 were also positive for the overexpression for mexB and 5/12 for mexY, respectively 
[239].  
Khalili et al. identified n = 23 Car-R/Ceph-S P. aeruginosa isolates (9.5% of tested 
isolates) over a three-year period (2016–2018). Efflux pump overexpression and β-
lactamase-production was assessed phenotypically: 60.9% showed efflux-pump 
overexpression, while AmpC-hyperproduction was shown in 4.3%. Overexpression of 
relevant efflux pumps was also verified by RT-PCR in 68.8% of isolates [240]. Lee et al. 
performed a retrospective, case-control study including patients with Car-R/Ceph-S and 
pan-susceptible P. aeruginosa bacteremia over a 6-year period (2004–2010): n = 25 patients 
were recorded with Car-R/Ceph-S bloodstream infections, their mortality was almost 
three times higher than the mortality of the control group (72% vs. 26%), and carbapenem-
resistance was found as the only independent risk factor for mortality [241]. In a 1-year 
prospective study on non-fermenting Gram-negatives in Egypt, Wafy et al. found n = 29 
isolates resistant to carbapenems (meropenem) via phenotypic assays; however, out of 
these isolates, only n = 15 were also resistant to antipseudomonal cephalosporins [242]. 
Rodulfo et al. aimed to compare the presence of the MDR and XDR phenotype in 
Pseudomonas with the occurrence of various virulence factors. In addition to the presence 
of Car-R/Ceph-S isolates (reported to be ~13% of the overall pool of isolates), their report 
highlighted the continuous increase in resistance rates to β-lactam antibiotics and class I 
integrons between 2009 and 2016 (37.1% vs. 50.0% for piperacillin-tazobactam, 32.3% vs. 
50% for ceftazidime, 33.9% vs. 50% for cefepime, 38.7% vs. 65.6% for imipenem, and 37.1% 
vs. 59.4% for meropenem). They have also found a positive association between the 
MDR/XDR phenotype and the presence of hemolysin, the exoU gene, and integrase I [243]. 
In the study of Khan et al., the resistance characteristics of keratitis-causing P. aeruginosa 
isolates, originating from Australia and India, were compared [73]. All of the isolates 
carried a β-lactam resistance gene (blaPAO), most of the Australian isolates carried blaOXA-
396, while other β-lactam resistance genes were also seen in both Australian and Indian 
Antibiotics 2021, 10, 42 17 of 28 
 
isolates (e.g., blaOXA-486, blaOXA-488, blaOXA-396, and blaOXA-50), although much less commonly. 
Resistance rates were 78% for imipenem and 57% for ceftazidime, and 58% for imipenem 
and 50% for ceftazidime in Indian and Australian isolates, respectively [73]. 
In one the most recent studies on the topic from Southern Hungary, the occurrence 
of Car-R/Ceph-S P. aeruginosa from UTIs was assessed over a 10-year surveillance period. 
Overall, fifty-seven such isolates were detected and these bacteria were characterized with 
phenotypic methods: 4/57 isolates produced carbapenemases, 7/57 isolates showed the 
overproduction of an AmpC β-lactamase, 31/57 overexpressed efflux pumps, while in the 
case of 15/57 isolates, no conclusive data could be obtained for the resistance determinants 
using the phenotypic methods included [244]. Interestingly, the first identified integron-
borne MBL was also identified from P. aeruginosa in Hungary [245]. Based on the reports 
described previously, there is a small but relevant number of Car-R Pseudomonas isolates 
(4–20 isolates/year, based on the abovementioned reports), where “older” generation β-
lactam antibiotics (i.e., ceftazidime and cefepime) may still be relevant to therapy. This 
allows for the special, more conscious use of these reserve agents. Choosing these agents 
instead of colistin offers a possibility for antimicrobial stewardship/colistin-sparing [246]. 
Whilst with a small margin, the superior susceptibility levels of ceftazidime and cefepime 
in P. aeruginosa were also recently highlighted in the International Network for Optimal 
Resistance Monitoring (INFORM) Surveillance Program (ceftazidime: 85.1%, cefepime: 
86.1%, meropenem: 80.2%) [247].  
Even though there is growing literature available on the topic, there is no consensus 
on the most common mechanisms of resistance contributing to the emergence of Car-
R/Ceph-S isolates. There are wide-ranging differences in the prevalence of 
carbapenemases (especially for MBLs), and this may affect the susceptibility to 
cephalosporins as well [73,230–244]. Khalili et al. proposed that the detection of Car-
R/Ceph-S isolates is dependent on the absence of carbapenemases [240]. Coupled with the 
low-to-moderate levels of AmpC production, these isolates may show susceptibility to 
ceftazidime and cefepime, as demonstrated in these reports. On the other hand, the 
importance of the OprD porin mutations in the presence of carbapenem resistance has 
been demonstrated by several studies. In fact, porin alterations are one of the most 
common resistance mechanisms after repeated exposure to carbapenems [176–189]. The 
cited literature reports highlight the importance of the continuous surveillance of bacterial 
pathogens possessing β-lactamases (including phenotypic and molecular methods) to aid 
antimicrobial stewardship interventions and to help in utilizing the safest and most 
appropriate therapeutic alternatives available [248]. 
4. Emerging Therapeutic Options for Pseudomonas Infections 
While there have been advances in the marketing authorization of novel antibiotics 
and combination therapy in the recent decade, their price and availability may hinder 
their widespread use in the near future. Additionally, it is questionable how long the new 
agents can manage the worsening resistance situation [146,157,249–254]. With the 
daunting increase in antimicrobial resistance rates in all types of bacteria, one of the main 
aims of antimicrobial research is the exploration for new approaches past conventional 
antibiotics, such as bacteriophages, antimicrobial peptides with diverse structures and 
mechanisms of action, virulence inhibitors, siderophores, compounds from natural 
origins (like essential oils), and other adjuvants (e.g., efflux pump inhibitors, monoclonal 
antibodies) (Table 3) [118,255–270]. It is possible that in the next couple of decades, these 
agents will play a major role in the management of serious bacterial infections caused by 
P. aeruginosa and other pathogens of critical importance. 
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Table 3. Novel and emerging therapeutic alternatives in P. aeruginosa [118,146,157,249–270]. 
Emerging therapeutic strategy Description (when relevant) 
Novel antibiotics, antibiotic 
combination therapy 
Ceftolozane/tazobactam, ceftazidim/avibactam, imipenem/cilastatin/relebactam, 
meropenem/vaborbactam, plazmomicin, delafloxacin 
Existing drugs in novel 
formulations 
Nebulized or liposomal tobramycin, levofloxacin, aztreonam lysine, fosfomycin, colistin, and 
lyposimal used to treat P. aeruginosa in the lungs of CF patients 
Phage therapy, endolysins 
Bactericidal, highly specific to target bacteria without affecting the commensal bacteria, 
effective against MDR isolates, synergistic activity with antibiotics, may penetrate dense 
biofilms. Endolysins: they degrade the bacterial peptidoglycan from the inside of the cell 
during the lytic cycle of phages. 
Siderophores, iron chelation 
Perturbation of irom metabolism has been proposed as an emerging therapeutic strategy. 
Gallium (Ga3+): clinical trials include iv. gallium-nitrate (GaNite) and co-encapsulation of Ga-
gentamicin in CF patients. 
The exact mechanism of action for Ga is still poorly understood. Some studies propose that 
Ga interferes with iron (Fe) uptake, Fe metabolism, and inhibits the function of Fe-containing 
respiratory enyzmes; however, this explanation was deemed unstatisfactory, as most 
compounds affecting Fe-metabolism or acting through chelation are bacteriostatic, while Ga 
has rapid bactericidal activity. Newer studies suggest that Ga treatment acts through the 
generation of ROS and the inhibition of antioxidant defence mechanisms in bacteria.  
Lectin inhibition Inhibition of LecA/LecB binding to lung epithelial cells. 
Quorum sensing (QS) 
inhibition, virulence inhibition 
Inhibition of signal molecule synthesis or sensing, which may hinder bacteria from adapting 
to diverse ecological niches, evading the immune system and producing virulence factors. 
Virulence inhibitors may “disarm” bacteria; therefore, they will not be able to induce their 
characteristic pathologies in vivo. In addition, as QS and virulence inhibitors do not target 
essential cellular components (which leads to high levels of selection pressure and the 
emergence of resistant mutants), it is unlikely that the host microbiome will be affected or that 
rapid resistance against these agents will occur. 
Efflux pump inhibitors 
 






Natural compounds, essential 
oils  
5. Concluding Remarks 
P. aeruginosa, an important member in the group of non-fermenting Gram-negative 
bacteria, has received substantial attention in recent years, associated with many different 
disease manifestations, especially in hospitalized and/or immunocompromised patients. 
The emergence of MDR, XDR, and PDR strains in P. aeruginosa is an important public 
health concern, leading to difficulties in therapeutic choices. β-lactam antibiotics are some 
of the most important drugs in the therapy of Pseudomonas infections, with a special focus 
on carbapenems, which have been considered as reserve antibiotics since their 
introduction in the 1980s [271]. Nevertheless, the global increase in the utilization of these 
drugs (both for infections caused by NFGNB and Enterobacterales) has led to the 
expansion of carbapenem-resistant strains in all parts of the world [272]. These 
developments should be considered very alarming. The occurrence of a specific 
resistotype of P. aeruginosa, namely carbapenem-resistant but cephalosporin-susceptible 
(Car-R/Ceph-S) strains, has received substantial interest, as these rare cases may offer 
opportunities for using older β-lactam antibiotics, instead of using other last-resort agents 
with more toxicity, and to limit the development of selection pressure on these bacteria. 
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